The latest news on clinical trials New York - Medical and Pharma Insider

Kryptos Biotechnologies raises $10 million for clinical studies for its point-of-care molecular diagnostics system

Point-of-care testing requires comprehensive requirements in accuracy, speed, cost, and usability

Clinical-stage oncology company, Boundless Bio prices initial public offering to raise $100 million

Boundless Bio is interrogating extrachromosomal DNA biology to deliver transformative therapies to patients

IGC Pharma closes $3 Million private placement to advance Alzheimer's treatment

IGC Pharma Inc. (“IGC”) is focused on Alzheimer's disease, developing innovative solutions to address this devastating illness.

Envoy Medical (NASDAQ: COCH) secures up to $10 million of debt to finance its cochlear implant clinical trial

The Esteem cochlear implant has no externally-worn components required for daily use which allows for “invisible hearing,”

Kenai Therapeutics closes $82 Million to advance next generation allogeneic cell therapies for neurological diseases, including Parkinson's

The Company utilizes allogeneic induced pluripotent stem cell (iPSC) technology, a Nobel Prize-winning breakthrough

Avation Medical unveils first non-invasive, closed-loop wearable neuromodulation for overactive bladder conditions

The Company’s Vivally System is the only FDA-cleared, closed-loop, at-home wearable neuromodulation device system

Clinical-stage Latigo Biotherapeutics raises $135 Million to develop non-opioid pain medicines

With the significant capital we've raised, we are positioned to build a company that provides new therapeutic options to patients with pain

Vancouver-based BIOVAXYS completes first tranche of financing, raising $1,103,500

BioVaxys is focusing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccinnation

Kiora Pharmaceuticals enters into a securities purchase agreement with institutional investors to raise approximately $45 Million

Kiora Pharmaceuticals is a biopharmaceutical company focused on developing therapeutics for patients with severe vision loss